Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Worldwide Revenue ($M) ($M)
Legacy standalone subsegment reported through Q4 2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 606 | +3.1% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 588 | +4.1% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 565 | +7.6% | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 525 | -2.1% | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 536 | +3.9% | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 516 | -8.0% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 561 | +1.4% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 553 | +0.5% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 550 | +7.2% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 513 | +8.5% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 473 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up point of care diagnostics (legacy standalone subsegment through fy2025q4 — i-stat & i-stat alinity) — worldwide revenue ($m)
- Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Organic / Comparable Sales Growth (%)3.1% · FY2025
- Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Reported Sales Growth (%)3.1% · FY2025
- Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Foreign Exchange Impact on Sales Growth (%)-0.2% · FY2023
- Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — U.S. Revenue ($M)422 · FY2025
- Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — International Revenue ($M)184 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-poc-leg-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.